^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Solid Tumor

    Related cancers:
    1d
    Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 ) (clinicaltrials.gov)
    P3, N=390, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • 5-fluorouracil • Padcev (enfortumab vedotin-ejfv) • mitomycin
    1d
    Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer (clinicaltrials.gov)
    P=N/A, N=2, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial primary completion date
    1d
    LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study (clinicaltrials.gov)
    P=N/A, N=75, Recruiting, University of Alberta | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial primary completion date
    1d
    PRIMROSE: A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=334, Recruiting, AstraZeneca | N=234 --> 334 | Trial completion date: Feb 2026 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Dec 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    EGFR negative
    |
    Datroway (datopotamab deruxtecan-dlnk)
    1d
    The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Stanford University
    New P1 trial
    1d
    Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Cdactin-O (CBM588) • zanzalintinib (XL092)
    1d
    Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (clinicaltrials.gov)
    P3, N=312, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd. | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    M701
    1d
    Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, University Hospital, Linkoeping | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    1d
    Brain Health in Breast Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    1d
    A Randomized Phase II Study of Priming Treatment With the Hedgehog Inhibitor NLM-001 Prior to Gemcitabine/Nab-Paclitaxel (GNab-P) plusBotensilimab and Balstilimab (Bot/Bal) Versus GNab-P in Patients With Previously Untreated Advanced Pancreatic Cancer (NUMANTIA-2) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Nelum Corp
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • NLM-001
    1d
    Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC (clinicaltrials.gov)
    P2, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    1d
    Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=474, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head